Skip to main content
. 2013 Sep 19;7:576. doi: 10.3389/fnhum.2013.00576

Table 4.

Characteristics of MI training studies for mobility and locomotor activities.

Res Prot/Study N TSS PP Mental practice Mean change scores
Hrs Hrs Eval Tasks Gait speed Limb ABC Berg DGI TUG (s)
cm/s L % 0–100 0–56 0–100
1BYoo and Chung, 2006 E 5 months 2.7 2.7 YES NO 1 NA 15 NA NA NA NA
Standing E 23 months 2.0 2.0 17
E 8 months 1.5 1.5 21
1BHwang et al., 2010 E:13 24 months 20 6–10 YES NO 1 7 NA 46 23 17 5
Gait C:11 23 months 20 2 10 8 1 3
1B Lee et al., 2011 E:13 Chronic 9 5–9 NO NO 1 16 NA NA NA NA NA
Gait C:11 9 No sham 10
1B Cho et al., 2013 E:15 45 months 9 6 NO NO 1 14 NA NA NA NA 8.3
Gait C:13 46 months No sham 9 1.6
2Malouin et al., 2004a E:12 Chronic 7 rep 35 rep YES YES 2 NA 16 NA NA NA NA
Rising-up/sitting
2Malouin et al., 2009 E:5 2.4 years 100 rep 1100 rep YES YES 2 NA 18 NA NA NA NA
Rising-up/sitting C:4 3.5 years 100 rep 0 rep −6
C:3 2.4 years 0 rep 0 rep 6
2 Deutsch et al., 2012 E:1 10 years 1 5 YES YES 35 11 NA NA 2
Gait
3Dunsky et al., 2008 E:17 9–108 months 0 3–4.5 NO YES 1 15 (8–38) NA NA NA NA NA
Gait
3Guttman et al., 2012 E:13 7–55 months ? 2.8–4 YES NO 1 NA 0 NA NA NA NA
STS
2Tamir et al., 2007 E:11 Stage 1.5–3 Hoen and Yahr's stage 12 12 NO NO 3 NA NA NA NA NA 2.5
Mobillity
Parkinson D C:10 24 −0.5
2Braun et al., 2011 E:25 *1.5–3 and <3 Hoen and Yahr's stage 5 6 NO NO ? 3 and 20 NA NA NA NA 1.5 and 1.3
Gait
Parkinson D C:22 5 14 and 18 3.4 and 1.0

PP, physical practice; TSS, mean time since stroke; Hrs, hours; Eval, MI assessment; ✓, manipulation checks; Tasks, number of tasks rehearsed mentally;

Res Prot 1A, 1B, 2, 3

, research protocols described in Table 1; NC, non-chronic strokes; Limb L, percent of limb loading on the affected side; STS, sit-to-stand; Berg, Berg balance scale; DGI, dynamic gait index; ABC, Activities-specific balance confidence scale; TUG, Timed Up and Go test; NA, not applicable; No sham, no contact time control; rep, repetitions;

*

results from 2 analyses: patients in stages 1.5–3 and patients in stages 1.5–2; bold, studies in persons with Parkinson's disease; ?, unspecified.